comprehensive -WSS

comprehensive

author：leisure time 2025-08-31 02:01:48 - browse：9

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Doudna institute plans to 'cure hundreds of diseases' with CRISPR

explore

WSS

Heart disease and mental health: A look at cardiac psychology

UnitedHealth sued over use of algorithm in Medicare Advantage plans

After decades in use, heart stents finally beat placebo

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

FDA reorg will put new emphasis on investigations, sources say

DeSantis can now import cheaper drugs. But will Biden get credit?

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Virginia high school admissions case could be legal follow

New Medicare drug pricing powers could soon be upended in court

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Zepbound, Valneva's vaccine, and more

In Memoriam: Notable people who died in 2023

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Medical leaders decry Supreme Court decision on affirmative action

Generative AI mines health records to identify patients’ social needs

hotspot

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

FDA reorg will put new emphasis on investigations, sources say

Publishing genetic code of viruses could cause disaster

Ohio still needs to do more to protect the right to abortion

Ohio still needs to do more to protect the right to abortion

A letter from the executive editor: STAT UnitedHealth investigation

hotspot

explore

focus

Wikipedia